|
PHAT | Phathom Pharmaceuticals, Inc. |
|
|
PHAT | Phathom Pharmaceuticals, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ -2.51 |
| Leverage | 180.46% |
| Market Cap | $ 337.4m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -345.0m |
| Margin | -423.03% |
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey.